Clinical Trials Logo

Clinical Trial Summary

Toxoplasmosis is one of the most common zoonotic diseases caused by the obligate intracellular parasite, T. gondii. It affects up to one-third of the world's population Horizontal transmission is mostly caused by ingestion of tissue cysts in infected meat, or through consumption of food or drink contaminated with sporulated oocysts, while vertical transmission occurs due to primary acquired maternal infection throughout pregnancy.In immunocompetent hosts, acquired infection is asymptomatic in more than 80% of cases, or is associated with fever,cervical lymphadenopathy, or myalgia. In immunocompromised patients,toxoplasmosis is always life-threatening where toxoplasmic encephalitis is the most important presentation. Among those patients, the disease may be caused by a newly acquired infection, reactivation following cyst rupture, donation of a cyst-containing organ from a seropositive donor to a seronegative recipient, or reactivation of dormant infection in the recipient Patients with hematological malignancy (HM), including those with acute myelogenous leukemia, and those who have undergone hematopoietic stem cell transplantation or treated with aggressive immunosuppressive regimens are at high risk of opportunistic infections The association between toxoplasmosis and cancers remains dual. Most cancer patients are in a state of impaired cellular and humoral immune systems either from the primary disease, or from chemotherapy and/or radiotherapy administration. Chemotherapeutic drugs work by killing both fast growing cancer cells, and healthy white blood cells causing neutropenia. So, patients receiving chemotherapy are more susceptible to Toxoplasma infections. Many studies have reported that the rate of reactivation of a latent T. gondii infection was higher in different types of cancers particularly those of the eye, brain, blood and breast. On the other side, T. gondii was also implicated as possible oncogenic pathogen with suggested role in induction and progression of malignant diseases. This was explained by many theories such as preventing apoptosis, enhancing the motility of dendritic cells and macrophages.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05963295
Study type Interventional
Source Sohag University
Contact nourhan m abd elhaliem, resident
Phone 01096779396
Email norhanmohamed@med.sohag.edu.eg
Status Not yet recruiting
Phase N/A
Start date August 2023
Completion date February 2025

See also
  Status Clinical Trial Phase
Completed NCT03258762 - Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects Phase 1
Completed NCT01479361 - Antiretroviral Drug Interaction Study in Volunteers With HIV Phase 1
Not yet recruiting NCT05860998 - Measuring the Prevalence of Toxoplasmosis and Its Socio-economic Consequences
Not yet recruiting NCT05783778 - Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris N/A
Not yet recruiting NCT04825600 - Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL) N/A
Completed NCT03993093 - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Recruiting NCT00004317 - Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis Phase 4
Withdrawn NCT03932656 - Latent Toxoplasmosis in Females With Borderline Personality Disorder
Not yet recruiting NCT06305468 - Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis
Completed NCT02011750 - Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia Phase 4